anti-Mullerian hormone receptor type 2
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der AMHR2 gene provides instructions for making the anti-Müllerian hormone (AMH) receptor type 2, which is involved in male sex differentiation. The AMH receptor type 2 is found on the surface of Müllerian duct cells. The Müllerian duct, found in both male and female fetuses, is the precursor to the female reproductive organs. During development of male fetuses, cells of the testes release a protein called the AMH protein. The AMH protein attaches (binds) to the AMH receptor type 2, which signals self-destruction (apoptosis) of the Müllerian duct cells. As a result, the Müllerian duct breaks down (regresses) in males. In females, who do not produce the AMH protein during fetal development, the Müllerian duct becomes the uterus and fallopian tubes.
Normal function
Der AMHR2 gene provides instructions for making the anti-Müllerian hormone (AMH) receptor type 2, which is involved in male sex differentiation. The AMH receptor type 2 is found on the surface of Müllerian duct cells. The Müllerian duct, found in both male and female fetuses, is the precursor to the female reproductive organs. During development of male fetuses, cells of the testes release a protein called the AMH protein. The AMH protein attaches (binds) to the AMH receptor type 2, which signals self-destruction (apoptosis) of the Müllerian duct cells. As a result, the Müllerian duct breaks down (regresses) in males. In females, who do not produce the AMH protein during fetal development, the Müllerian duct becomes the uterus and fallopian tubes.
Conditions referring to this gene or chromosome
Other names
AMH type II receptor
AMHR
AMHR2_HUMAN
anti-Muellerian hormone type II receptor
anti-Muellerian hormone type-2 receptor
anti-Mullerian hormone receptor type II
anti-Mullerian hormone receptor, type II
MIS type II receptor
MISR2
MISRII
MRII
Mullerian inhibiting substance type II receptor
Related patient information and medicines

Patient information leaflet
Kehlkopfkrebs
Kehlkopfkrebs is a general term used to describe cancers of the throat. It is sometimes called laryngeal cancer (cancer of the larynx). Dr Krishna Vakharia, 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred.

Patient information leaflet
Mundkrebs
Mundkrebs is also sometimes called oral cancer. Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore,... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or.

Patient information leaflet
Behandlung von Typ-2-Diabetes
If a high blood sugar level is brought down to a normal level, your symptoms will ease and your risk of long-term complications will be much lower. Managing Typ-2-Diabetes Keeping your blood sugar (glucose) well controlled is key to reducing your risk of long-term complications such as heart, kidney or eye problems. Regardless of whether you need.

Patient information leaflet
Akute Pankreatitis
(In chronic pancreatitis, the inflammation is persistent - it tends to cause less intense symptoms than acute pancreatitis but has longer lasting symptoms). How common is acute pancreatitis. Between 13-45 in 100,000 people have acute pancreatitis each year in the UK. Acute pancreatitis has become more common in recent years. This is partly due to.

Patient information leaflet
Erkrankungen der Hypophyse
This leaflet gives a brief overview of the pituitary gland und der Hormone it makes. The pituitary gland is found at the base of the brain and is 'pea-sized'. The pituitary gland is an overall controller of a number of other glands in the body, overseeing the function of these organs through hormones. Some of the pituitary gland disorders.

Patient information leaflet
Nierenkrebs
A description of what Nieren sind und how they work is at the bottom of this article. What is kidney cancer. There are several types of kidney cancer but over 9 out of 10 kidney cancers are "renal cell cancer". This is sometimes called renal adenocarcinoma or renal cell carcinoma or hypernephroma. Renal cell cancer This type of cancer develops.
Weiterführende Lektüre und Referenzen
- anti-Mullerian hormone receptor type 2; MedlinePlus, National Library of Medicine.
- Faure E, Gouedard L, Imbeaud S, Cate R, Picard JY, Josso N, di Clemente N. Mutant isoforms of the anti-Mullerian hormone type II receptor are not expressed at the cell membrane. J Biol Chem. 1996 Nov 29;271(48):30571-5. doi: 10.1074/jbc.271.48.30571.
- Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N, Picard JY. A 27 base-pair deletion of the anti-mullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum Mol Genet. 1996 Sep;5(9):1269-77. doi: 10.1093/hmg/5.9.1269.
- Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update. 2005 Jul-Aug;11(4):351-6. doi: 10.1093/humupd/dmi014. Epub 2005 May 5.
- Josso N, Picard JY, Imbeaud S, di Clemente N, Rey R. Clinical aspects and molecular genetics of the persistent mullerian duct syndrome. Clin Endocrinol (Oxf). 1997 Aug;47(2):137-44. doi: 10.1046/j.1365-2265.1997.2411044.x. No abstract available.
- Rey R. Anti-Mullerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol. 2005 Feb;49(1):26-36. doi: 10.1590/s0004-27302005000100005. Epub 2006 Mar 16.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Mar 2011 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

